user-generated· earnings
Pfizer’s menopause drug Astellas’ Veozah outperforms in Q3 2026 trials
Market overview
Veozah, a non-hormonal treatment for moderate-to-severe vasomotor symptoms, will show statistically significant superiority over placebo in late-stage trial results due by Q3 2026. Wall Street anticipates these results to drive a 15%+ stock rally for both Pfizer and Astellas.
earnings prediction market
- Implied probability (Yes)
- 72%
- Closes
- 2026-09-30
More earnings markets
- Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes
- Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
- Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
- Titleist sells more clubs than Callaway in 2026 — 72% Yes
- Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
- Lime achieves profitability within 12 months post-IPO — 55% Yes
- SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
- SpaceX AI division revenue exceeds $500M in 2025 — 65% Yes
Loading…